Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply by Authors.
Tremblay S, Summers-Trasiewicz L, Pouliot F, Crook JM, Ding K, Klotz L, Toren P. Tremblay S, et al. Among authors: crook jm. J Urol. 2021 Nov;206(5):1176. doi: 10.1097/JU.0000000000001946.03. Epub 2021 Aug 12. J Urol. 2021. PMID: 34383590 No abstract available.
Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer.
Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg SL. Bruchovsky N, et al. Clin Genitourin Cancer. 2008 Mar;6(1):46-52. doi: 10.3816/CGC.2008.n.008. Clin Genitourin Cancer. 2008. PMID: 18501083 Clinical Trial.
Intermittent androgen suppression for rising PSA level after radiotherapy.
Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. Crook JM, et al. N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546. N Engl J Med. 2012. PMID: 22931259 Free PMC article. Clinical Trial.
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.
Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M, Crook JM. Klotz L, et al. Among authors: crook jm. J Clin Oncol. 2015 Apr 1;33(10):1151-6. doi: 10.1200/JCO.2014.58.2973. Epub 2015 Mar 2. J Clin Oncol. 2015. PMID: 25732157 Free PMC article. Clinical Trial.
Editorial Comment.
Crook J. Crook J. J Urol. 2019 Jun;201(6):1133. doi: 10.1097/01.JU.0000554393.69622.3c. J Urol. 2019. PMID: 30817222 No abstract available.
Intermediate-risk Prostate Cancer: Stratification and Management.
Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D'Amico AV. Preisser F, et al. Eur Urol Oncol. 2020 Jun;3(3):270-280. doi: 10.1016/j.euo.2020.03.002. Epub 2020 Apr 14. Eur Urol Oncol. 2020. PMID: 32303478 Review.
359 results